Foghorn Therapeutics Inc. (FHTX) company profile
Close on Nov 16, 2026Market cap $106.30MP/E –Yield –
About Foghorn Therapeutics
Pharmaceutical Preparations, SIC 2834
Foghorn is a clinical-stage biotechnology enterprise that develops precision therapeutics designed to treat serious diseases, primarily cancers. The company targets the chromatin regulatory system to correct aberrant gene expression orchestrating disease progression. Leveraging its proprietary Gene Traffic Control platform, Foghorn identifies genetically determined dependencies within diseased cells to discover and design small molecule drug candidates, such as enzymatic inhibitors, targeted protein degraders, and transcription factor disruptors. Its lead candidate, FHD-909, is an orally administered selective SMARCA2 inhibitor undergoing Phase 1 clinical testing for non-small cell lung cancer and solid tumors in collaboration with Eli Lilly and Company.
The company advances multiple preclinical and clinical programs across several oncology targets, including SMARCA2, CBP, EP300, and ARID1B. Foghorn conducts its operations with a workforce of 106 employees as of late 2025. It maintains collaborative research, development, and commercialization agreements covering the United States market. The provided text does not disclose the location of the company's headquarters or other geographic facilities.
Summary of the business section of Foghorn Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Foghorn Therapeutics Inc.
- Headquarters
- Cambridge, MA
- Address
- 500 Technology Square, Suite 700 02139
- Phone
- (617) 586-3100
- Website
- foghorntx.com
- Employees
- 106, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte& Touche LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- FHTX
- Exchange
- Nasdaq
- IPO date
- Oct 23, 2020
- Shares outstanding
- 59M, Jul 31, 2026
- Public float
- $172.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1822462
- CUSIP
- 344174107
- ISIN
- US3441741077
- FIGI
- BBG00HFZPB88
- Share class FIGI
- BBG00HFZPB97
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Adrian Gottschalk | Chief Executive Officer, Director | 511,704 |
| Ryan D. Maynard | Chief Financial Officer | – |
| Anna Rivkin | Chief Business Officer | – |
| Michael LaCascia | Chief Legal Officer | – |
| Carlos Costa | Chief People Officer | 0 |
| Alfonso Quintas Cardama | Chief Medical Officer | – |
| Steven F. Bellon | Chief Scientific Officer | 151,957 |
| Kristian Humer | Chief Financial Officer | – |
| Thomas J. Lynch Jr. | Director | – |
| Scott Biller | Director | – |
| Michael Mendelsohn | Director | – |
| Neil Gallagher | Director | – |
| Stuart Duty | Director | – |
| Simba Gill | Director | 34,061 |
| Ian F. Smith | Director | 72,072 |
| B. Lynne Parshall | Director | – |
| Douglas G. Cole | Director | – |
| Flagship Ventures Fund V, L.P. | Director | – |
| Noubar Afeyan | Director | – |
| Ventures Fund V. General Partner LLC Flagship | Director | – |
| Flagship Pioneering, LLC | Director | – |
| Ventures Opportunities Fund I. General Partner LLC Flagship | Director | 9,330,878 |
| Flagship Pioneering Special Opportunities Fund II, L.P. | Director | – |
| Flagship Ventures Opportunities Fund I, L.P. | Director | – |
| Pioneering Special Opportunities Fund II General Partner LLC Flagship | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $2.36M | $3.07M | $1.17M | $84 | – |
| FY2024 | $1.56M | $2.38M | $1.68M | $73 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Adrian Gottschalk President and Chief Executive Officer | $638.00K | $1.33M | $385.99K | $3.00K | $2.36M | +51% |
| Steven Bellon Chief Science Officer | $505.00K | $469.26K | $222.20K | $3.00K | $1.20M | +33% |
| Alfonso Quintás-Cardama Chief Medical Officer | $494.00K | $419.61K | $217.36K | $3.00K | $1.13M | +47% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 23, 2020
- Offer price
- $16.00
- Securities offered
- 7,500,000
- Gross proceeds
- $120.00M
- Exchange
- Nasdaq
- First trading day
- Oct 23, 2020
- First-day close
- $18.12+13.3%
- Lock-up ends (est.)
- Apr 21, 2021
“The initial public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 106 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 24, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 23, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 19, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?